oNDV-IL12

oNDV-IL12 is a genetically engineered **oncolytic Newcastle Disease Virus** (oNDV) that is modified to express **interleukin-12 (IL-12)**, a potent proinflammatory cytokine. It is designed as a cancer immunotherapy agent. The **mechanism of action** involves direct oncolysis of tumor cells via viral infection and lysis, as well as local delivery of IL-12 cytokine within the tumor microenvironment, which enhances T cell–mediated antitumor immunity. Specifically, oNDV-IL12 has been shown to sensitize tumor cells to chimeric antigen receptor T cell (CAR-T) therapy and to enhance CAR-T cell persistence and antitumor effect. The agent’s utility has been demonstrated in preclinical models, particularly for **non-small cell lung cancer (NSCLC)**, where it increases Th1 cytokine production (notably IFNγ, granzyme B, and perforin) and CD8+ T cell effector signatures within tumors. As a monotherapy, oNDV-IL12 displays limited antitumor effect but shows strong synergy in combination with adoptive cell therapies. The local expression of IL-12 by oNDV overcomes dose-limiting toxicities observed with systemic recombinant IL-12. The developer information is not specified in publicly available sources, but the referenced research appears to come from academic or translational oncology research groups[1][3].

Other names

oNDV-IL12oNDV-IL-12oNDV-IL 12